(Q35529369)

English

Ultra-rapid virological response, young age, low γ-GT/ALT-ratio, and absence of steatosis identify a subgroup of HCV Genotype 3 patients who achieve SVR with IFN-α(2a) monotherapy

scientific article published on 13 October 2011

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Ultra-rapid virological response, young age, low γ-GT/ALT-ratio, and absence of steatosis identify a subgroup of HCV Genotype 3 patients who achieve SVR with IFN-α(2a) monotherapy (English)

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

0 references

1 reference

based on heuristic

inferred from title

Giuliano Ramadori

8

object named as

Giuliano Ramadori

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

7

object named as

Sabine Mihm

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

author name string

Ahmad Amanzada

1

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Armin Goralczyk

2

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Federico Moriconi

3

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Martina Blaschke

4

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Inga-Marie Schaefer

5

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

David van Thiel

6

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

13 October 2011

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Digestive Diseases and Sciences

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

56

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

11

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

3296-3304

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Immediate virological response predicts the success of short-term peg-interferon monotherapy for chronic hepatitis C

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3208815

27 July 2018

APRI as a predictor of early viral response in chronic hepatitis C patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3208815

27 July 2018

IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3208815

27 July 2018

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3208815

27 July 2018

Peginterferon alfa-2a and ribavirin in Latino and non-Latino whites with hepatitis C.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3208815

27 July 2018

Early predictors of anemia in patients with hepatitis C genotype 1 treated with peginterferon alfa-2a (40KD) plus ribavirin

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3208815

27 July 2018

Randomized comparison of 12 or 24 weeks of peginterferon alpha-2a and ribavirin in chronic hepatitis C virus genotype 2/3 infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3208815

27 July 2018

Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3208815

27 July 2018

Treatment of genotype 2 and 3 chronic hepatitis C virus-infected patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3208815

27 July 2018

Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3208815

27 July 2018

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3208815

27 July 2018

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3208815

27 July 2018

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3208815

27 July 2018

African Americans with genotype 1 treated with interferon for chronic hepatitis C have a lower end of treatment response than Caucasians

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3208815

27 July 2018

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3208815

27 July 2018

Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3208815

27 July 2018

Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3208815

27 July 2018

Factors predictive of a beneficial response to therapy of hepatitis C.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3208815

27 July 2018

Dose-dependent acute clearance of hepatitis C genotype 1 virus with interferon alfa

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3208815

27 July 2018

Classification of chronic hepatitis: diagnosis, grading and staging

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3208815

27 July 2018

A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1933-2

21 January 2018

Peginterferon alfa-2a in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1933-2

21 January 2018

Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1933-2

21 January 2018

A randomized, prospective trial of ribavirin 400 mg/day versus 800 mg/day in combination with peginterferon alfa-2a in hepatitis C virus genotypes 2 and 3.

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1933-2

21 January 2018

Peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a monotherapy in early virological responders and peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a, ribavirin and amantadine triple therapy in early virological nonre

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1933-2

21 January 2018

Treatment of chronic hepatitis C with interferon alone or combined with ribavirin in Japan

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1933-2

21 January 2018

Virological response is associated with decline in hemoglobin concentration during pegylated interferon and ribavirin therapy in hepatitis C virus genotype 1.

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1933-2

21 January 2018

Interferon regulatory factor-1 promoter polymorphism and the outcome of hepatitis C virus infection.

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1933-2

21 January 2018

Predictive value of the IL28B polymorphism on the effect of interferon therapy in chronic hepatitis C patients with genotypes 2a and 2b.

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1933-2

21 January 2018

IL28B genetic variation and treatment response in patients with hepatitis C virus genotype 3 infection

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1933-2

21 January 2018

Analysis of histopathological manifestations of chronic hepatitis C virus infection with respect to virus genotype

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1933-2

21 January 2018

Preferential virological response to interferon-alpha 2a in patients with chronic hepatitis C infected by virus genotype 3a and exhibiting a low gamma-GT/ALT ratio

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1933-2

21 January 2018

Reduced dose and duration of peginterferon alfa-2b and weight-based ribavirin in patients with genotype 2 and 3 chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1933-2

21 January 2018

Efficacy of pegylated interferon-α2a monotherapy in Japanese children with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1933-2

21 January 2018

Pegylated interferon-alpha-2a plus ribavirin for treatment-naive Asian patients with hepatitis C virus genotype 1 infection: a multicenter, randomized controlled trial.

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1933-2

21 January 2018

High sustained response rate in patients with histologically mild (low grade and stage) chronic hepatitis C infection. A randomized, double blind, placebo controlled trial of interferon alpha-2b with and without ribavirin.

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1933-2

21 January 2018

Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1933-2

21 January 2018

Role of interleukin-28B polymorphisms in the treatment of hepatitis C virus genotype 2 infection in Asian patients

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1933-2

21 January 2018

Association of IL28B variants with response to pegylated-interferon alpha plus ribavirin combination therapy reveals intersubgenotypic differences between genotypes 2a and 2b.

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1933-2

21 January 2018

Early virologic response and IL28B polymorphisms in patients with chronic hepatitis C genotype 3 treated with peginterferon alfa-2a and ribavirin.

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1933-2

21 January 2018

Effect of interferon-alpha induction therapy on genotype 2b/3a and low viral load hepatitis C virus infection. A randomized multicentre study

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1933-2

21 January 2018

Efficacy of interferon monotherapy to 394 consecutive naive cases infected with hepatitis C virus genotype 2a in Japan: therapy efficacy as consequence of tripartite interaction of viral, host and interferon treatment-related factors

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1933-2

21 January 2018

Ratio of serum gamma-GT/ALT rather than ISDR variability is predictive for initial virological response to IFN-alpha in chronic HCV infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3208815

26 September 2018

Randomized trial comparing three different regimens of alpha-2a-interferon in chronic hepatitis C. The TriVeneto Viral Hepatitis Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3208815

26 September 2018

Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alfa therapy in chronic hepatitis C.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3208815

26 September 2018

High sustained virologic response rate after interferon monotherapy in Japanese hepatitis C patients with a low HCV RNA titer and/or HCV genotype 2. A prospective study

1 reference

https://pubmed.ncbi.nlm.nih.gov/21994136

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Peginterferon-α-2a (40KD) and Ribavirin for 16 or 24 Weeks in Patients With Genotype 2 or 3 Chronic Hepatitis C

1 reference

https://pubmed.ncbi.nlm.nih.gov/21994136

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S10620-011-1933-2

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35529369&oldid=2197447521"